Fig. 7

Inhibition of VEGFR1/2-mediated signaling after treatment with PBS, GNP, VGB3 or GNP–VGB3 in 4T1 mammary carcinoma tumor-bearing mice. All of the measurements were done at the end of the treatment period (day 32). a Tumor lysates were probed and quantitatively analyzed for levels of total and phosphorylated VEGFR1 and VEGFR2. b Representative images and quantitative analysis of CD31 as microvessel formation index (Scale bar = 20 µm). c Tumor lysates were probed and quantitatively analyzed with the indicated antibodies. d Representative images and quantitative analysis of Ki67 as tumor proliferation index (Scale bar = 100 µm). e Tumor lysates were probed and quantitatively analyzed with the indicated antibodies. f Representative images of TUNEL and the statistical graph based on the percentage of apoptosis cells (Scale bar = 100 µm). g Tumor lysates were probed and quantitatively analyzed with the indicated antibodies. All data were analyzed by prism software (One-way ANOVA method, mean ± SD, n = 3, number sign symbol (#) was used for comparing the treatments with control, and asterisk symbol (*) was used for comparison between treatments ****P < 0.0001, ***P < 0.001, **P < 0.01,*P < 0.1, ns: not significant compared to untreated control)